AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

By Colin Kellaher

AbbVie on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its recently acquired Elahere cancer drug for certain adults with ovarian cancer.

AbbVie said the CHMP's positive opinion covers patients with folate receptor alpha-positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior treatment regimens.

The European Commission, which generally follows the CHMP's advice, is expected to make a final decision by the end of the year.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed earlier this year. AbbVie reported global Elahere net revenue of $128 million in the second quarter.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 20, 2024 08:27 ET (12:27 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.